What Sixera Pharma Does
Sixera Pharma is a biopharmaceutical company based at the Karolinska Institute Science Park in Stockholm. The company was founded to develop basic research findings into treatments for skin diseases.
About Netherton syndrom
What is Netherton syndrom?
OBS: skriv om, kopierat från google
Netherton disease is a rare disorder affecting the skin, hair and immune system. Symptoms are present at birth and include red, scaly skin. Other symptoms include outbreaks of red, circular scaly rashes, thin, fragile hair (bamboo hair), and immune reactions such as hay fever, asthma, itchy skin, and eczema. Dehydration and infection are common and can be serious.
Babies tend to grow slowly and have poor weight gain. Netherton syndrome is caused by the SPINK5 gene not working correctly. It is inherited in an autosomal recessive pattern. Netherton syndrome is diagnosed based on clinical examination, the symptoms, and genetic testing.
The symptons starts early
Some examples of Netherton syndrom symptoms
Want to learn more about the symptons?
01.
Abnormal hair morphology
Nisl tempus, sollicitudin amet, porttitor erat magna congue dui malesuada vestibulum.
02.
Acanthosis nigricans
Ultrices et ultrices enim nunc, quis pellentesque sit mauris turpis augue vitae
03.
Asthma
Nisl tempus, metus, sollicitudin amet, porttitor erat magna congue dui malesuada vestibulum.
04.
Congenital nonbullous ichthyosiform erythroderma
Nisl tempus, metus, sollicitudin amet, porttitor erat magna congue dui malesuada vestibulum.
05.
Eczema
Nisl tempus, metus, sollicitudin amet, porttitor erat magna congue dui malesuada vestibulum.
06.
Fine hair
Nisl tempus, metus, sollicitudin amet, porttitor erat magna congue dui malesuada vestibulum.
Sixera Pharma and Netherton syndrom
Improving lives with our discovery
The founders of Sixera Pharma discovered key genes and the mechanisms regulating skin formation and barrier functions critical for the Netherton syndrome. The discovery resulted in the development of a new treatment of the disease, which is of great importance as no targeted treatment is available for the disease today. The new treatment is expected to drastically improve the quality of life for Netherton patients, which is an extremely vulnerable group of patients.
The clinical development of the treatment is carried out through a network of academic and industrial collaborations backed up by comprehensive pre-clinical work, along with development of regulatory documentation
- This means that children can get a normal life
- other benefit of your research
The team has a combined experience of 30+ years
We develop drugs that restore the balance in diseased skin.
Felis ipsum arcu rutrum auctor diam pellentesque tellus dolor nunc, ut sem gravida urna nunc augue ullamcorper eleifend nibh tellus iaculis tempus, nec nec molestie habitant risus, eros, gravida habitasse ipsum tincidunt turpis sed cursus integer porttitor pretium, augue suspendisse.
We are always looking for new ways to connect
If you are in a position to help our project or know someone that should be on our team you can contact us here.
News from the team
Nec habitasse sociis urna urna dignissim et ac parturient sed mi ultricies porttitor ligula eu elementum arcu leo, cum tellus suspendisse dignissim habitant pellentesque.
Sixera initiates its first clinical trial on SXR1096 in Netherton Syndrome
with the potential to be the first available treatment of the rare and serious skin disease Netherton syndrome Stockholm, December 7, 2021. The Swedish biotech
The start of something new
Welcome to our newly launched website were we will make it possible for you to follow our work and take part of insights from our
